T he article by Pere Berbel and his Spanish coworkers, published in this issue of Thyroid (1), is fascinating both for the results reported and its clever study design, unique among all other studies published so far on the consequences of iodine deficiency (ID) during pregnancy. Because this study combines data on specific maternal aspects with information on infant neurodevelopment, the present editorial was written jointly by two authors representing these different disciplines. ID is considered to be one of the most frequent causes of preventable mental retardation in children worldwide. Because ID is now recognized as a major public health issue for both maternal and fetal=child health, micronutrient fortification with dietary iodine has been listed as priority number 3 among 30 proposals that constitute major worldwide challenges for which solutions presently exist. These proposals, entitled ''2008 Copenhagen Consensus,'' have been recently established by a panel of eight of the world's most distinguished economists, including five Nobel laureates (2).
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The developing brain needs thyroid hormone (TH) throughout pregnancy and TH receptors are present in fetal brain tissue as early as the first trimester. Limited TH secretion does not occur until the second trimester, hypothalamopituitary regulation of TH production not until the third trimester, and full function not until term. Consequently, the fetal brain has to rely on maternal supply of TH and this reliance continues until delivery (3) . During the first trimester of pregnancy, maternal thyroxine (T 4 ) is the fetus's only source of T 4 , whereas by the third trimester mother and fetus both supply T 4 . In fetal brain, the active TH interacting with nuclear receptors is triiodothyronine, derived from maternal T 4 by deiodination. Epidemiological studies have shown that children born to women with mild to moderate hypothyroxinemia exhibit neurological alterations and reduced IQ scores, as well as an increased incidence of attention problems (4) . Because of the central role of iodine in TH production, children whose mothers had mild to moderate ID may also be at risk. Indeed, a recent study of children from a region in Sicily with mild to moderate ID reported an association between first trimester ID and reduced IQ as well as attention deficit hyperactivity disorder in as many as two thirds of the children (5). However, because most studies were carried out in the context of maternal hypothyroidism (i.e., with elevated serum TSH) or isolated hypothyroxinemia (i.e., with normal serum TSH), and in light of the review by Glinoer and Delange (6) also reporting subtle neuro-psychiatric and intellectual deficits in infants=children born to mothers residing in conditions with mild to moderate ID, further study is warranted (7) .
In the study by Berbel et al.
(1), the authors examined the consequences of a period of isolated hypothyroxinemia in pregnant women from a coastal region in Spain that had mild ID. In this study, mothers of all children were given dietary iodine fortification, but the timing varied. The authors hypothesized that a brief delay in instituting iodine fortification would still lead to disturbed offspring neurodevelopment since the time window was beyond when most neocortical proliferation, which requires TH, had occurred. The study design was quite complicated and deserves close scrutiny to comprehend the findings. In particular, the inclusion criteria involved a number of successive selection=exclusion steps. The original cohort consisted of 345 pregnant women who were stratified into three groups on the basis of their serum free T 4 levels (normal range: 0.71-1.85 ng=dL) and the time when iodine supplementation (with 200 mg KI orally per day) was introduced. In all groups, iodine supplementation continued until end of breast-feeding. Eighteen months after delivery, a neurodevelopmental evaluation was carried out on a restricted group of highly selected infants.
Group 1 encompassed 92 women who were enrolled at 4-6 weeks gestation and received iodine supplementation throughout pregnancy until discontinuing breast-feeding. From this group, 64 women (70%) who did not have hypothyroxinemia were first identified and from them, 43 women with a serum free T 4 above the 20th percentile at both 4-6 weeks gestation and term were selected. Next, to establish homogeneity across groups, select children were excluded for presence of specific factors (other than maternal hypothyroxinemia) that might have a negative impact either before or after birth, on subsequent neurodevelopment. The list of exclusion criteria included factors relating to medical history during gestation, at delivery and during lactation; nutritional 1 Endocrine Division, Saint Pierre Hospital, Free University of Brussels, Brussels, Belgium. habits as well as drug intake; children's health up until the 18-month assessment; and familial socio-economic environment, leading to 23 eligible cases. Of these, a further 10 were lost to follow-up, leaving a final sample size of 13 infants in group 1. These children represent therefore a subpopulation born to women whose pregnancies took place in the most adequate possible thyroid conditions, namely with normal serum free T 4 levels and iodine supplementation from early on and onwards.
Group 2 encompassed 102 women, who were enrolled at 12-14 weeks gestation and were iodine-supplemented from this time until discontinuing breastfeeding. Within this group, 29 women (28%) with initially isolated hypothyroxinemia were selected (serum free T 4 levels between the 0th and 10th percentile). In the next step, 21 women whose serum free T 4 levels were above the 20th percentile at term remained selected. The third step, which involved applying the strict exclusion criteria for nonthyroid factors, led to the elimination of a further seven cases and two more were lost to follow-up. Thus there were 12 infants from this group who underwent neurodevelopmental evaluation. These infants therefore represent a subpopulation born to mothers with a less favorable pregnancy in terms of the adequacy of maternal thyroid function-compared to group 1-because of transient hypothyroxinemia during early gestation and an additional 6-10 weeks gestation period before starting iodine supplementation. It is surprising (and the authors provide no explanation for this) that the proportion of hypothyroxinemic women in group 2 was not substantially larger than group 1 (28.4% vs. 30.4%) since, if their hypothyroxinemia resulted from ID, we would expect repercussions of ID on maternal thyroid function to become more frequent and severe as gestation progressed (8) .
Group 3 encompassed 151 women who were enrolled at term (37-40 weeks) and only received iodine supplementation from this time until lactation ended. Within this group, 57 women (37.7%) with isolated hypothyroxinemia at term were selected. It is noteworthy that the proportion of hypothyroxinemic women was greater in this group (37.7%) than in groups 1 and 2 (30.4% and 28.4%, respectively), presumably as a consequence of the lack of iodine supplementation during gestation. Next, 40 of the 57 women remained selected on the basis of having a serum free T 4 between the 0th-10th percentile at term. The third selection step, applying the exclusion criteria for nonthyroid factors, led to the elimination of 19 cases, with a further two lost to follow-up, eventually leaving 19 infants (18 þ 1, because there was a twin pregnancy) for neurodevelopmental assessment. These infants therefore represent a subpopulation born to mothers whose pregnancy took place in the least favorable thyroid conditions, with hypothyroxinemia at term (and supposedly also before) and iodine supplementation started only after delivery.
Before discussing the study results, we need to comment on the specific population of pregnant women in this study. First, with regard to free T 4 levels, it is not clear whether this range represents a normal nonpregnant population or the manufacturer's reference range for the assay used or else a range specifically dedicated to free T 4 determinations during pregnancy. Regardless, the 0th-10th percentile interval ranged between 0.71 and 0.82 ng=dL, the 10th-20th percentile interval between 0.83 and 0.91 ng=dL, and the 20th-100th percentile interval between 0.92 and 1.85 ng=dL.
Second, with regard to women's serum free T 4 values, the prevalence of hypothyroxinemic women was remarkably high, ranging between 28.4% (group 2) and 37.7% (group 3). Taken together in the three groups, one third of the women presented a serum free T 4 in the 0th-10th percentile at one or another gestational stage, with 6.5-9.9% of women having a serum free T 4 below the lower limit of normality (<0.71 ng=dL). This extraordinarily high prevalence of isolated hypothyroxinemia is unusual and points to several unanswered questions. Why was the prevalence so high in this study, clearly much more elevated than in any other similar study? Also, since the authors assumed that this abnormality was essentially due to ID, why did serum TSH not increase, particularly since progressive changes in serum TSH constitute the hallmark feature of ID during pregnancy (9) . Furthermore, why did only six cases within the entire cohort of 345 women have a serum TSH >4.8 mU=L? Finally, why did authors not investigate the neurodevelopmental status of children born to women with the more severe pattern of isolated hypothyroxinemia, namely those born to the 22 women in group 1 who had an early serum free T 4 between the 0th-10th percentile and those born to the 28 women with a serum free T 4 below normal at one or another gestational stage (6 cases in group 1, 7 cases in group 2, and 15 cases in group 3). Together, these women could have potentially constituted a fourth strong group of 50 women with more severe hypothyroxinemia than those presently selected by the authors, and still with a normal serum TSH. Comparing the neurodevelopmental outcome of the latter infants with those from groups 1 to 3 could have provided highly relevant information, especially that their mothers had been managed applying the same scheme of iodine supplementation.
Third, with regard to women's iodine status, it is worth noting that only one spot measurement was sampled at delivery for the determination of urinary iodine excretion (UIE). UIE was lowest (as expected) in group 3, who had a mean value of 75 mg=L, compared with groups 1 and 2 whose mean UIE values were significantly higher due to iodine supplementation (121 and 97 mg=L, respectively). It remains puzzling, however, that the UIE ranges were not different between the three groups, because we would have expected UIE values to be shifted to the right (i.e., with higher range limits) in the groups who received 200 mg of KI during pregnancy. Also despite the iodine supplements provided in groups 1 and 2 during gestation, the frequencies of women with UIE <50 mg=L were not different, reaching 20% in all three groups. These considerations raise the concern that the authors could not objectively assess whether iodine supplements were regularly taken by all women during the entire length of the study.
Fourth, in contrast to the above comments on iodine status, the relationship between thyroid function tests and iodine supplementation given during pregnancy was clear. In groups 1 and 2, respectively, 95.6% and 85.7% of the women had a serum free T 4 above the 20th percentile at term and none were found to be hypothyroxinemic, in sharp contrast with group 3 women of whom 37.7% were hypothyroxinemic at term. However, despite a significantly lower mean serum free T 4 in group 3 at delivery (0.77 ng=dL) than in groups 1 and 2 (1.02 ng=dL), it is surprising that serum TSH values were the same in the three groups at delivery: 2.10-2.23 mU=L (note that these values were reported only for mothers whose infants later underwent neurodevelopmental assessment).
GUEST EDITORIAL
To summarize the maternal thyroid function aspect of this study, group 1 consisted of women whose serum free T 4 levels were above the 20th percentile at both 4-6 weeks and term; group 2 were women characterized by transient hypothyroxinemia at 12-14 weeks, with serum free T 4 levels above the 20th percentile at term; group 3 were women characterized by hypothyroxinemia at term, with serum free T 4 between the 0th-10th percentile; all women had normal serum TSH levels. Unfortunately, no information was available concerning maternal thyroid function before 12-14 weeks in group 2 and before delivery in group 3, two inherent weaknesses of present study since the authors assumed that hypothyroxinemia had also been present before the first TH measurements in these two study groups.
Across the groups, approximately 50% of eligible infants, after exclusionary criteria and accounting for drop-outs, were evaluated at 18 months of age using the revised Brunet-Lézine scale. There is no explanation for or analysis of the large number who were eligible but refused participation at this age. Thus from an original sample of 345 women, fewer than 15% of their children were studied. Despite this small number of children, developmental differences were clearly significant with the highest development quotient (DQ) being seen in group 1 (DQ ¼ 102), followed by group 2 (DQ ¼ 92) and group 3 as the lowest (DQ ¼ 88). The differences between groups 2 and 3 were not significant, however. Additionally among the three groups, only groups 2 and 3 contained children with delayed neurodevelopment.
In addition to these global developmental quotient scores, the Brunet-Lézine test also provides four subscales assessing gross motor development, fine motor coordination, language skills, and socialization abilities. Children in the present study differed on gross motor, fine motor, and socialization quotients, with the lowest scores being achieved by groups 2 and 3. The lack of difference on the language scale among groups may be due to the young age of the children with respect to emergence of varying aspects of language skill or the possibility that the neural substrates of these abilities are either less sensitive to TH influence or perhaps the time period needed for TH action occurs later during development (including postnatally). For example in children with congenital hypothyroidism, language skills are more sensitive to a delay in achieving euthyroidism than to the severity of hypothyroidism at diagnosis (10) . The present finding of a role of hypothyroxinemia on socialization is especially interesting in view of associations between autism and possible environmentally mediated hypothyroxinemia (11) . Furthermore, the rise in incidence of ADHD and its association with ID (5) as well as attention problems associated with maternal hypothyroidism (4) may suggest a similar thyroid-mediated mechanism for this prevalent disorder. Indeed, among children with congenital hypothyroidism, several groups have shown an association between their high rate of attention problems (12) and the severity of hypothyroidism at birth (13) .
Despite the inherent weaknesses as well as a sophisticated and quite complicated design leading to elimination of more than 85% of the children born to the women who were initially enrolled in the study, and in spite of several criticisms raised above, this article has considerable merit. This study shows for the first time differences in infants' outcome associated with isolated hypothyroxinemia (i.e., in the presence of normal serum TSH levels), in an area with mild ID. It is important to note that none of the women whose children were studied had serum free T 4 levels below normality at any time (at least when measured). Whatever the cause of their hypothyroxinemia (which remains somewhat of a mystery), the present results indicate that a brief delay of just a few weeks during early gestation in initiating iodine fortification increases the risk of neurodevelopmental delays in the offspring and to almost the same level as in those whose mothers were not iodine-supplemented until term. If confirmed by further studies on a larger scale and with a more detailed sequential follow-up of thyroid function tests during pregnancy, this work not only conveys the message that dietary iodine fortification is important throughout pregnancy, especially at the beginning, but it also supports the recommendation of an urgent daily supplement of iodine to all women when considering conception. In the randomized clinical trial carried out in Brussels in 1994, with iodine supplementation given to mildly to moderately ID pregnant women, it was shown that there was a lag period of one trimester before observing a clear improvement in maternal thyroid function parameters, and this prompted the authors to insist on the recommendation to fortify dietary iodine as early as possible, ideally before the onset of a pregnancy (14) . The present study confirms that this recommendation was justified not only for maternal health, but also for the offspring.
